CG Oncology (NASDAQ:CGON) Upgraded to Sell at Wall Street Zen

Posted by Francis Steltz on Nov 8th, 2026

Wall Street Zen upgraded shares of CG Oncology (NASDAQ:CGON – Free Report) from a strong sell rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on the company. Truist Financial boosted their price objective on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Royal Bank Of Canada lowered their price objective on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a report on Wednesday, July 29th. Piper Sandler lifted their target price on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research report on Thursday, October 15th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CG Oncology has an average rating of “Moderate Buy” and an average price target of $87.50.

View Our Latest Research Report on CGON

CG Oncology Stock Up 17.3%

CG Oncology stock opened at $75.99 on Friday. The company’s 50-day moving average price is $68.23 and its 200-day moving average price is $66.09. The company has a market cap of $6.74 billion, a PE ratio of -27.53 and a beta of 0.35. CG Oncology has a twelve month low of $35.80 and a twelve month high of $80.97.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.55 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. As a group, sell-side analysts expect that CG Oncology will post -3.31 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the completion of the sale, the director owned 1,000 shares in the company, valued at approximately $62,060. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 3,000 shares of company stock valued at $209,580. 4.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CG Oncology

Hedge funds have recently added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new position in CG Oncology in the 2nd quarter valued at $718,000. Legal & General Group Plc purchased a new stake in CG Oncology in the second quarter worth $2,846,000. Jefferies Financial Group Inc. purchased a new stake in CG Oncology in the second quarter worth $54,705,000. Jupiter Topco LLC bought a new stake in shares of CG Oncology during the second quarter worth $1,634,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of CG Oncology during the second quarter worth $16,584,000. 26.56% of the stock is currently owned by institutional investors.

Key CG Oncology News

Here are the key news stories impacting CG Oncology this week:

Positive Sentiment: CG Oncology reported a third-quarter loss of $0.64 per share, narrower than analysts’ estimates of about $0.83–$0.86 per share. Zacks earnings report
Positive Sentiment: Revenue was $1.6 million, above the approximately $0.55 million analysts expected, further supporting the favorable market reaction. CG Oncology Gains on Q3 Results
Neutral Sentiment: The quarterly loss widened from $0.57 per share a year earlier to $0.64, despite beating current estimates. Investors should weigh that ongoing loss against the earnings and revenue surprises. Zacks earnings report

CG Oncology Company Profile

(Get Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biotechnology company focused on developing therapies for bladder cancer and other cancers affecting the urinary tract. The company is developing medicines designed to stimulate the immune system and target tumor cells within the bladder.

Its lead product candidate is cretostimogene grenadenorep, an investigational intravesical therapy based on an oncolytic adenovirus. The treatment is designed to be administered directly into the bladder, where it may selectively infect cancer cells, promote their destruction and activate an immune response against the tumor.